UK Medicines Regulator Awards Innovation Passport to Base-Editing Candidate for Heart Disease
Verve Therapeutics announced yesterday that its most advanced base-editing candidate VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) by the UK Medicines and Healthcare products Regulatory Agency. VERVE-101 is designed as a single-dose cure for HeFH, and is currently being evaluated in the heart-1 trial in the UK ad New Zealand.